Drug Trial Radar · NCT07936487
IIIb Trial for RC28-E Injection in Participants With DME and wAMD
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
350
Planned (sponsor's estimate)
Start
Oct 30, 2026
Primary completion
Dec 1, 2028
Study completion Jun 30, 2029
Sponsor
- Lead sponsor
- RemeGen Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to primarily determine the safety profile of RC28-E in participants with DME and wAMD. Also explore the efficacy.
Conditions
- Diabetic Macular Edema (DME)
- wAMD
Interventions
RC28-EBiological
Ophthalmic solution for intravitreal injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Severity of Ocular/ Non-ocular Adverse Event.Time frame: 52 week
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.